Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,900.00-1.51%ETH$2,404.54-3.20%GOLD$4,387.30+1.26%OIL$103.71-2.00%
Smart Investors Daily
GE

NASDAQ · GERN

Geron Corporation

Healthcare · Biotechnology

$1.31

Down-$0.06 (-4.38%)

Updated Sep 16, 2026, 9:17 AM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
884.12M
P/E ratio
-11.55
Dividend yield
0.00%
52-week range
$1.04 – $2.01
Volume
16.49M
Avg. volume
7.6M

Price performance

GERN price history

1M range · 20 trading sessions · Daily adjusted prices

GERN closed at $1.31 after 20 trading sessions, down 14.38% for the selected period.

Last close
$1.31
Period change
-14.38%
Period low
$1.31
Period high
$1.59
Daily close
View OHLC price history
GERN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$1.37$1.37$1.30$1.3116.49M
Sep 14, 2026$1.36$1.395$1.344$1.3712.12M
Sep 11, 2026$1.385$1.41$1.34$1.359.87M
Sep 10, 2026$1.39$1.405$1.36$1.377.69M
Sep 9, 2026$1.50$1.51$1.40$1.409.24M
Sep 8, 2026$1.55$1.58$1.50$1.518.31M
Sep 4, 2026$1.49$1.59$1.46$1.5711.48M
Sep 3, 2026$1.58$1.60$1.48$1.5114.23M
Sep 2, 2026$1.49$1.62$1.48$1.5926.89M
Sep 1, 2026$1.47$1.495$1.46$1.487.89M
Aug 31, 2026$1.50$1.51$1.45$1.497.25M
Aug 28, 2026$1.53$1.53$1.49$1.517.42M
Aug 27, 2026$1.54$1.56$1.50$1.537.88M
Aug 26, 2026$1.58$1.58$1.50$1.539.12M
Aug 25, 2026$1.55$1.59$1.50$1.559.84M
Aug 24, 2026$1.53$1.55$1.44$1.5213.11M
Aug 21, 2026$1.56$1.57$1.50$1.524.43M
Aug 20, 2026$1.58$1.59$1.54$1.555.99M
Aug 19, 2026$1.57$1.59$1.525$1.598.02M
Aug 18, 2026$1.52$1.559$1.51$1.534.24M

Latest GERN news

The latest Smart Investors Daily articles mentioning GERN.

Stock researchCompany · Overview

GERN research

Overview

Company profile and research snapshot.

Company profile

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.89
Implied upside
—
Analysts
—
GERN recent ratings
DateFirmRatingTarget
Nov 5, 2025NeedhamBuy—
Jul 10, 2025Goldman SachsSell—
May 8, 2025ScotiabankSector Perform—
Mar 12, 2025HC Wainwright & Co.Neutral—
Mar 12, 2025NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Geron to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference:Fireside Chat on Wednesday, September 9, 2026, at 8:00 a.m. ET in New York, NY H.C. Wainwright 28th Annual Global Investmen

Yahoo · Jul 22, 2026

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options to purchase an aggregate of 202,500 shares of common stock to five newly hired employees as an inducement material to such employees’ acceptance of employment with Geron. The stock options have an exercise price of $1.44 per share, which is equal to the closing price of Geron’s common stock on

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By